Condition: Leukemia · Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies. Taking advantage of a next generation sequencing (NGS) platform, screening for known and unknown mutations potentially associated with the disease will be done. The screening will be performed on affected and unaffected family members, in order to outline new pedigrees that either validate previous findings or constitute novel discoveries.
This description comes directly from the study's public registry record.
Domenico Russo, MD · 0039303996811 · domenico.russo@unibs.it
Francesca Schieppati, MD · 0039303996811 · fschieppati@gmail.com
Always discuss trial participation with your own doctor first.
| Chair of Hematology and Bone marrow Transplant Unit | Brescia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03058588